The Food and Drug Administration approved Cytokinetics’ Myqorzo, marking the company’s first approved drug and setting up a direct commercial competitor to Bristol Myers Squibb’s Camzyos. Cytokinetics positioned Myqorzo as an alternative therapy for the same cardiovascular indication targeted by Camzyos, which is tracking toward more than $1 billion in annual sales. The approval represents a validation of Cytokinetics’ development strategy and will shift the competitive landscape in the indication, with downstream pricing, market access and real‑world uptake to determine commercial outcomes.